ArticleFrontiers in immunology2026
Case Report: Cholangioscopic and histopathological findings before and after treatment in immune-related cholangitis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Immune-related cholangitis is a rare immune-related adverse event, and its diagnostic criteria and treatment strategies have not yet been established. Here, we report a case of immune-related cholangitis in which treatment response could be objectively visualized through reassessment of cholangioscopic and histopathological findings before and after treatment. A 79-year-old man with recurrent cutaneous squamous cell carcinoma of the scalp developed high fever and general fatigue after six courses of nivolumab, and laboratory tests revealed marked elevation of hepatobiliary enzymes. Contrast-enhanced computed tomography and endoscopic ultrasonography showed bile duct wall thickening, endoscopic retrograde cholangiopancreatography demonstrated shaggy irregularity in the distal bile duct, and peroral cholangioscopy revealed diffuse surface irregularity and granular changes of the biliary mucosa. Furthermore, cholangioscopy-guided bile duct biopsy demonstrated marked lymphocytic infiltration, particularly infiltration of CD8-positive T cells, leading to a diagnosis of immune-related cholangitis. Prednisolone and ursodeoxycholic acid were initiated, with nivolumab discontinued, after which the clinical symptoms and hepatobiliary enzyme levels gradually improved. Furthermore, on Day 28 after treatment initiation, reassessment by cholangioscopy and bile duct biopsy confirmed improvement in the cholangioscopic findings and reduction of lymphocytic infiltration, particularly CD8-positive T-cell infiltration, on bile duct biopsy. These objective findings supported tapering of steroid therapy. To our knowledge, very few cases have described reassessment of cholangioscopic and histopathological findings before and after treatment in immune-related cholangitis. We suggest that such evaluation may contribute to confirming treatment response and guiding therapeutic strategy in immune-related cholangitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.